BE1003002A6 - Formulation to be applied for the treatment of baldness and methods makinguse thereof - Google Patents

Formulation to be applied for the treatment of baldness and methods makinguse thereof Download PDF

Info

Publication number
BE1003002A6
BE1003002A6 BE8900305A BE8900305A BE1003002A6 BE 1003002 A6 BE1003002 A6 BE 1003002A6 BE 8900305 A BE8900305 A BE 8900305A BE 8900305 A BE8900305 A BE 8900305A BE 1003002 A6 BE1003002 A6 BE 1003002A6
Authority
BE
Belgium
Prior art keywords
emi
composition according
composition
antagonist
hair
Prior art date
Application number
BE8900305A
Other languages
French (fr)
Original Assignee
Coppe Jan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coppe Jan filed Critical Coppe Jan
Priority to BE8900305A priority Critical patent/BE1003002A6/en
Application granted granted Critical
Publication of BE1003002A6 publication Critical patent/BE1003002A6/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

Formulation comprising one Ca antagonist agent and at least one H2antagonist agent, along with a pharmaceutically inert excipient and ifrequired standard pharmaceutical adjuvants, for the application of atherapeutic treatment method for the human or animal body, particularlybaldness and hair loss, and the corresponding cosmetic formulation.

Description

       

  Composition à mettre en oeuvre pour le traitement de la calvitie, et procédés faisant usagé de celle-ci. 

  
On connaît depuis quelques temps une composition permettant de stimuler la croissance des cheveux, et comprenant, comme substance active, -du minoxidil (6-amino-1,2-dihydro-1-hydroxy2-imino-4-pipéridinopyrimidine) (voir US-A-4139619).

  
On connaît également une composition destinée au même but et comprenant, comme substance active, de la nifédipine
(1,4-dihydro-2,6-diméthyl-4-(2-nitrophényl)-2,6-diméthyl-3,5-dicar-

  
 <EMI ID=1.1> 

  
présente l'inconvénient. de l'apparition d'une rougeur sur certaines parties de la peau du visage, après l'application du produit connu.

  
Le minoxidil est aussi connu comme agent antihypertenseur et vasodilatateur artérien (The Index Merck, lOème éd., 1983, pages 888 et 889). La nifédipine est aussi connue comme médicament cardiaque à activité de blocage du calcium et comme vasodilatateur coronarien (The Index Merck, lOème éd., 1983, p.
936 et 937).

  
Les compositions mentionnées ci-dessus apportent certes - une certaine solution aux problèmes posés par la calvitie et la perte des poils et cheveux. Il faut toutefois noter que leur action reste moyenne et ne répond pas toujours aux besoins de l'utilisateur.

  
La présente invention a pour but de mettre au point une composition améliorée permettant la mise en oeuvre d'une méthode de traitement thérapeutique du corps humain ou animal, et notamment de la calvitie et de la perte des poils et cheveux.

  
Elle a également pour but une composition cosmétique, à mettre en oeuvre notamment dans le traitement de la calvitie ou de la perte des poils et cheveux, ainsi que son procédé d'applica-tion dans le but d'améliorer l'apparence physique de celui auquel on l'administre.

  
La présente invention, qui a trait à un domaine dont il est difficile de trancher s'il est thérapeutique ou cosmétique, concerne donc les deux domaines simultanément. 

  
Pour résoudre les problèmes posés, on prévoit suivant l'invention une composition comprenant au moins un agent

  
 <EMI ID=2.1> 

  
qu'un excipient physiologiquement inerte et éventuellement des adjuvants courants en pharmacie, pour la mise en oeuvre d'une méthode de traitement thérapeutique du corps humain ou animal, notamment de la calvitie -et de la perte des poils et cheveux.

  
Suivant - une forme de réalisation de l'invention, cette composition comprend, comme antagoniste du calcium, de la nifédipine, du vérapamil ou du diltiazem, et/ou leurs sels physiologiquement compatibles, ou un mélange de ces composés.

  
Suivant une autre forme de réalisation de l'invention, cette composition comprend, comme antagoniste du H2, de la cimétidine et/ou de la ranitidine et/ou leurs sels physiologiquement compatibles, ou un mélange de ces composés.

  
Suivant une forme avantageuse de. réalisation de l'invention, la composition se présente sous la forme d'un médicament à usage externe à appliquer par voie locale, en particulier sous forme de crème, de lotion, de shampoing, de produit à pulvériser.

  
On prévoit également, suivant l'invention, un procédé pour améliorer l'apparence physique d'un mammifère, et notamment d'un être humain, comprenant l'administration à celui-ci d'une composition contenant au moins un agent antagoniste du calcium et au

  
 <EMI ID=3.1> 

  
quantités appropriées pour stimuler la croissance des poils ou cheveux, et le renouvellement de la dose administrée jusqu'à l'obtention de l'amélioration esthétique recherchée. Avantageusement, l'administration est effectuée par application locale sur la peau.

  
Suivant l'invention, on prévoit aussi une composition cosmétique comprenant au moins un agent antagoniste du calcium et au moins un agent antagoniste de H2, ainsi qu'un excipient inerte, et éventuellement des adjuvants cosmétiques courants.

  
Suivant une forme préférée de l'invention, la composition se présente sous une forme à usage externe à appliquer par voie locale, en particulier sous forme de crème, de lotion, de shampoing, de produit à pulvériser. 

  
 <EMI ID=4.1> 

  
Index Merck, lOème éd., 1983, p. 1171 et 1172).

  
Comme antagonistes du Ca on utilise avantageusement suivant l'invention par exemple de la nifédipine déjà décrite précédemment,du vérapamil ou du diltiazem.

  
 <EMI ID=5.1> 

  
comme médicament cardiaque à activité de blocage du calcium, comme vasodilatateur coronarien et comme dépressif cardiaque, anti-arythimique (The Index Merck, lOème éd., 1983, p. 1421).

  
Le diltiazem (3-(acétyloxy)-5-[2-(diméthylamino)-

  
 <EMI ID=6.1> 

  
est connu comme médicament cardiaque à activité de blocage du calcium et comme vasodilatateur coronarien (The Index Merck, lOème éd., 1983, p. 466).

  
Il est entendu que les sels pharmaceutique ment compatibles de ces substances actives sont également utilisables, et qu'on peut également prévoir des mélanges d'antagonistes du

  
 <EMI ID=7.1>  du Ca permettait d'obtenir une action stimulante sur la croissance des poils et cheveux qui dépassait nettement l'action obtenue par la seule nifédipine. L'amélioration nette et l'effet synergique des composants actifs mélangés sont perçus en particulier sur la rapidité de croissance des cheveux et la densité des cheveux au stade de croissance terminale.

  
Avantageusement la composition est prévue pour une application locale et elle se présente par exemple sous la forme d'une crème, d'une lotion, d'un produit à pulvériser ou d'un shampoing. Elle comprend donc, outre les substances actives, des excipients  neutres ou compatibles et éventuellement des adjuvants courants en pharmacie ou dans le domaine cosmétique.

  
La nifédipine et la cimétidine présentent le grand avantage d'être sans danger pour la santé aux concentrations utilisées pour une application locale.

  
Avantageusement, on peut par exemple prévoir des compositions comprenant 0,5 - 3,5 % en poids de nifédipine et 0,5 - 2,5 % en poids de cimétidine, par rapport à la composition globale.

  
De préférence, une telle composition comprend 2 % de nifédipine et 1 % de cimétidine.

  
Cette composition est à appliquer 2 à 3 fois par jour, sur la peau du patient. Après une apparition de duvet, celui-ci se transforme rapidement en cheveux ayant atteint un stade de croissance terminale.

  
L'invention va être illustrée ci-dessous par quelques exemples de réalisation non limitatifs de l'invention.

Exemple 1

  

 <EMI ID=8.1> 
 

  

 <EMI ID=9.1> 

Exemple 2

  

 <EMI ID=10.1> 


  
 <EMI ID=11.1> 

  

 <EMI ID=12.1> 

Exemple 4

  

 <EMI ID=13.1> 

Exemple 5

  

 <EMI ID=14.1> 
 

REVENDICATIONS

  
1. Composition comprenant au moins un agent

  
 <EMI ID=15.1> 

  
qu'un excipient pharmaceutiquement inerte et éventuellement des adjuvants courants en pharmacie, pour la mise en oeuvre d'une méthode de traitement thérapeutique du corps humain ou animal, notamment de.la calvitie et de la perte des poils et cheveux.



  Composition to be used for the treatment of baldness, and methods making use of it.

  
A composition has been known for some time for stimulating hair growth, and comprising, as active substance, minoxidil (6-amino-1,2-dihydro-1-hydroxy2-imino-4-piperidinopyrimidine) (see US- A-4139619).

  
There is also known a composition intended for the same purpose and comprising, as active substance, nifedipine
(1,4-dihydro-2,6-dimethyl-4- (2-nitrophenyl) -2,6-dimethyl-3,5-dicar-

  
 <EMI ID = 1.1>

  
has the disadvantage. the appearance of redness on certain parts of the skin of the face, after application of the known product.

  
Minoxidil is also known as an antihypertensive agent and arterial vasodilator (The Index Merck, 10th ed., 1983, pages 888 and 889). Nifedipine is also known as a cardiac drug with calcium blocking activity and as a coronary vasodilator (The Index Merck, 10th ed., 1983, p.
936 and 937).

  
The compositions mentioned above certainly provide - some solution to the problems posed by baldness and hair loss. However, it should be noted that their action remains average and does not always meet the needs of the user.

  
The object of the present invention is to develop an improved composition allowing the implementation of a method of therapeutic treatment of the human or animal body, and in particular of baldness and loss of body hair and hair.

  
It also aims at a cosmetic composition, to be used in particular in the treatment of baldness or hair and hair loss, as well as its application process with the aim of improving the physical appearance of that to which it is administered.

  
The present invention, which relates to a field which it is difficult to decide whether it is therapeutic or cosmetic, therefore relates to both fields simultaneously.

  
To solve the problems posed, there is provided according to the invention a composition comprising at least one agent

  
 <EMI ID = 2.1>

  
that a physiologically inert excipient and possibly adjuvants common in pharmacy, for the implementation of a method of therapeutic treatment of the human or animal body, in particular of baldness and loss of hair and hair.

  
Next - an embodiment of the invention, this composition comprises, as an antagonist of calcium, nifedipine, verapamil or diltiazem, and / or their physiologically compatible salts, or a mixture of these compounds.

  
According to another embodiment of the invention, this composition comprises, as H2 antagonist, cimetidine and / or ranitidine and / or their physiologically compatible salts, or a mixture of these compounds.

  
According to an advantageous form of. embodiment of the invention, the composition is in the form of a medicament for external use to be applied locally, in particular in the form of a cream, lotion, shampoo, spray product.

  
According to the invention, a method is also provided for improving the physical appearance of a mammal, and in particular of a human being, comprising the administration to the latter of a composition containing at least one calcium antagonist agent. and at

  
 <EMI ID = 3.1>

  
appropriate amounts to stimulate the growth of hair or hair, and the renewal of the administered dose until the desired aesthetic improvement is obtained. Advantageously, the administration is carried out by local application to the skin.

  
According to the invention, a cosmetic composition is also provided comprising at least one calcium antagonist and at least one H2 antagonist, as well as an inert excipient, and optionally common cosmetic adjuvants.

  
According to a preferred form of the invention, the composition is in a form for external use to be applied locally, in particular in the form of a cream, lotion, shampoo, spray product.

  
 <EMI ID = 4.1>

  
Merck Index, 10th ed., 1983, p. 1171 and 1172).

  
As Ca antagonists, advantageously according to the invention are used, for example, nifedipine already described above, verapamil or diltiazem.

  
 <EMI ID = 5.1>

  
as a cardiac drug with calcium blocking activity, as a coronary vasodilator and as a cardiac depressant, anti-arythimic (The Index Merck, 10th ed., 1983, p. 1421).

  
Diltiazem (3- (acetyloxy) -5- [2- (dimethylamino) -

  
 <EMI ID = 6.1>

  
is known as a cardiac drug with calcium blocking activity and as a coronary vasodilator (The Index Merck, 10th ed., 1983, p. 466).

  
It is understood that the pharmaceutically compatible salts of these active substances can also be used, and that it is also possible to provide mixtures of antagonists of the

  
 <EMI ID = 7.1> of Ca made it possible to obtain a stimulating action on the growth of body hair and hair which clearly exceeded the action obtained by the single nifedipine. The clear improvement and the synergistic effect of the mixed active components are perceived in particular on the speed of hair growth and the density of the hair at the terminal growth stage.

  
Advantageously, the composition is intended for local application and it is for example in the form of a cream, a lotion, a product to be sprayed or a shampoo. It therefore includes, in addition to the active substances, neutral or compatible excipients and possibly common adjuvants in pharmacy or in the cosmetic field.

  
Nifedipine and cimetidine have the great advantage of being harmless to health at the concentrations used for local application.

  
Advantageously, it is possible, for example, to provide compositions comprising 0.5 - 3.5% by weight of nifedipine and 0.5 - 2.5% by weight of cimetidine, relative to the overall composition.

  
Preferably, such a composition comprises 2% of nifedipine and 1% of cimetidine.

  
This composition is to be applied 2 to 3 times a day, on the patient's skin. After the appearance of down, it quickly turns into hair that has reached a terminal growth stage.

  
The invention will be illustrated below by a few non-limiting exemplary embodiments of the invention.

Example 1

  

 <EMI ID = 8.1>
 

  

 <EMI ID = 9.1>

Example 2

  

 <EMI ID = 10.1>


  
 <EMI ID = 11.1>

  

 <EMI ID = 12.1>

Example 4

  

 <EMI ID = 13.1>

Example 5

  

 <EMI ID = 14.1>
 

CLAIMS

  
1. Composition comprising at least one agent

  
 <EMI ID = 15.1>

  
that a pharmaceutically inert excipient and optionally adjuvants common in pharmacy, for the implementation of a method of therapeutic treatment of the human or animal body, in particular of baldness and loss of body hair and hair.


    

Claims (1)

2. Composition selon la revendication 1, caractérisée en ce qu'elle comprend, comme antagoniste du calcium, de la nifédipine, du vérapamil ou du diltiazem, et/ou leurs seuls physiologiquement compatibles, ou un mélange de ces composés. 2. Composition according to claim 1, characterized in that it comprises, as calcium antagonist, nifedipine, verapamil or diltiazem, and / or their only physiologically compatible, or a mixture of these compounds. 3. Composition selon l'une des revendications 1 3. Composition according to one of claims 1 à 2, caractérisée en ce qu'elle comprend, comme antagoniste de H2, de la cimétidine ou de la ranitidine, et/ou leurs sels physiologiquement compatibles, ou un mélange de ces composés. to 2, characterized in that it comprises, as H2 antagonist, cimetidine or ranitidine, and / or their physiologically compatible salts, or a mixture of these compounds. 4. Composition selon l'une des revendications 1 4. Composition according to one of claims 1 à 3, caractérisée en ce qu'elle comprend 0,5 à 3,5 % en poids de nifédipine, de préférence 2 %, et 0,5 à 2,5 % en poids de cimétidine, de préférence 1 %, par rapport à la composition globale. to 3, characterized in that it comprises 0.5 to 3.5% by weight of nifedipine, preferably 2%, and 0.5 to 2.5% by weight of cimetidine, preferably 1%, relative to the overall composition. 5. Composition selon l'une des revendications 1 à 4, caractérisée en ce qu'elle se présente sous la forme d'un médicament à usage externe à appliquer par voie locale, en particulier sous forme de crème, de lotion, de shampoing, de produit à pulvériser. 5. Composition according to one of claims 1 to 4, characterized in that it is in the form of a medicament for external use to be applied locally, in particular in the form of cream, lotion, shampoo, of spray material. 6. Utilisation d'un agent antagoniste du Ca et <EMI ID=16.1> 6. Use of a Ca antagonist agent and <EMI ID = 16.1> pharmaceutique à mettre en oeuvre dans le traitement de la calvitie ou de la perte des poils ou cheveux. pharmaceutical to be used in the treatment of baldness or hair loss. 7.. Procédé pour améliorer l'apparence physique d'un mammifère, et notamment d'un être humain, comprenant l'administration à celui-ci d'une composition contenant au moins un agent 7. A method for improving the physical appearance of a mammal, and in particular of a human being, comprising the administration to the latter of a composition containing at least one agent <EMI ID=17.1>  <EMI ID = 17.1> qu'un excipient inerte, en quantités appropriées pour stimuler la croissance des poils ou cheveux, et le renouvellement de la dose administrée jusqu'à l'obtention de l'amélioration esthétique recherchée. an inert excipient, in appropriate amounts to stimulate the growth of hair or hair, and the renewal of the administered dose until the desired aesthetic improvement is obtained. 8. Procédé suivant la revendication 7, caractérisé en ce qu'il comprend l'administration de la composition susdite par application locale sur la peau. 8. Method according to claim 7, characterized in that it comprises the administration of the above-mentioned composition by local application to the skin. <EMI ID=18.1>  <EMI ID = 18.1> un agent antagoniste du calcium et au moins un agent antagoniste de H2, ainsi qu'un excipient inerte, et éventuellement des adjuvants cosmétiques courants. a calcium antagonist and at least one H2 antagonist, as well as an inert excipient, and optionally common cosmetic adjuvants. <EMI ID=19.1>  <EMI ID = 19.1> sa mise en oeuvre dans le traitement de la calvitie ou de la perte des poils et cheveux. its implementation in the treatment of baldness or hair loss. 11. Composition selon l'une des revendications 9 et 10, caractérisée en ce qu'elle comprend, de la nifédipine, du vérapamil ou du diltiazem, et/ou leurs sels physiologiquement compatibles, ou un mélange de ces composés. 11. Composition according to one of claims 9 and 10, characterized in that it comprises, nifedipine, verapamil or diltiazem, and / or their physiologically compatible salts, or a mixture of these compounds. 12. Composition selon l'une des revendications 9 à 11, caractérisée en ce qu'elle comprend, comme antagoniste 12. Composition according to one of claims 9 to 11, characterized in that it comprises, as an antagonist <EMI ID=20.1>  <EMI ID = 20.1> quement compatibles, ou un mélange de ces composés. only compatible, or a mixture of these compounds. 13. Composition selon l'une des revendications 9 à 12, caractérisée en ce qu'elle comprend 0,5 à 3,5 % en poids de nifédipine, de préférence 2 %, et 0,5 à 2,5 % en poids de cimétidine, de préférence 1 %, par rapport à la composition globale. 13. Composition according to one of claims 9 to 12, characterized in that it comprises 0.5 to 3.5% by weight of nifedipine, preferably 2%, and 0.5 to 2.5% by weight of cimetidine, preferably 1%, relative to the overall composition. 14. Composition selon l'une des revendications 9 à 13, caractérisée en ce qu'elle se présente sous une forme à usage externe à appliquer par voie locale, en particulier sous forme de crème, de lotion, de shampoing, de produit à pulvériser. 14. Composition according to one of claims 9 to 13, characterized in that it is in a form for external use to be applied locally, in particular in the form of cream, lotion, shampoo, spray product. .
BE8900305A 1989-03-21 1989-03-21 Formulation to be applied for the treatment of baldness and methods makinguse thereof BE1003002A6 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BE8900305A BE1003002A6 (en) 1989-03-21 1989-03-21 Formulation to be applied for the treatment of baldness and methods makinguse thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE8900305A BE1003002A6 (en) 1989-03-21 1989-03-21 Formulation to be applied for the treatment of baldness and methods makinguse thereof

Publications (1)

Publication Number Publication Date
BE1003002A6 true BE1003002A6 (en) 1991-10-22

Family

ID=3884081

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8900305A BE1003002A6 (en) 1989-03-21 1989-03-21 Formulation to be applied for the treatment of baldness and methods makinguse thereof

Country Status (1)

Country Link
BE (1) BE1003002A6 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717980A3 (en) * 1994-12-23 1999-01-07 ATELIER DYNAMIQUE S.r.l. Use of guanidine-imidazole derivatives to assist hair growth stimulation
EP1053745A1 (en) * 1999-05-18 2000-11-22 L'oreal Use of at least a calcium-channel-inhibitor in the treatment of wrinkles
EP1250927A2 (en) 1997-02-24 2002-10-23 S.L.A. Pharma AG Pharmaceutical composition for topical application comprising nifedipine
WO2008009860A2 (en) * 2006-07-21 2008-01-24 L'oreal Use of calcium channel antagonist compounds for depigmenting the skin
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US7829572B2 (en) 2006-10-04 2010-11-09 Pfizer Inc Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717980A3 (en) * 1994-12-23 1999-01-07 ATELIER DYNAMIQUE S.r.l. Use of guanidine-imidazole derivatives to assist hair growth stimulation
EP1250927A2 (en) 1997-02-24 2002-10-23 S.L.A. Pharma AG Pharmaceutical composition for topical application comprising nifedipine
US8318721B2 (en) 1997-02-24 2012-11-27 S.L.A. Pharma Ag Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US8906903B2 (en) 1997-02-24 2014-12-09 S.L.A. Pharma Ag Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
EP1053745A1 (en) * 1999-05-18 2000-11-22 L'oreal Use of at least a calcium-channel-inhibitor in the treatment of wrinkles
FR2793681A1 (en) * 1999-05-18 2000-11-24 Oreal USE OF AT LEAST ONE INHIBITOR OF AT LEAST ONE CALCIUM CHANNEL IN THE TREATMENT OF WRINKLES
US6344461B1 (en) 1999-05-18 2002-02-05 Societe L'oreal S.A. Treating skin wrinkles/fine lines with calcium channel inhibitors
US6908925B2 (en) 1999-05-18 2005-06-21 L'oreal Treating skin wrinkles/fine lines with calcium channel inhibitors
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
WO2008009860A2 (en) * 2006-07-21 2008-01-24 L'oreal Use of calcium channel antagonist compounds for depigmenting the skin
WO2008009860A3 (en) * 2006-07-21 2009-06-18 Oreal Use of calcium channel antagonist compounds for depigmenting the skin
US7829572B2 (en) 2006-10-04 2010-11-09 Pfizer Inc Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists

Similar Documents

Publication Publication Date Title
CA1341267C (en) Combination of pyrimidine and salicylic acid derivatives to induce and stimulate hair growth and reduce hair loss
JP2001526200A (en) Compositions and methods for the treatment of alopecia
KR101467568B1 (en) Pharmaceutical solution containing minoxidil with enhanced dermal retention and hair growing effect
JPS62155205A (en) Fungicidal manicure liquid
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
ATE322878T1 (en) GALENIC FORMULATION CONTAINING BIOTIN
FR2744017A1 (en) ASSOCIATIONS OF PEROXIDIC LIPIDS AND ORGANOSILIC COMPOUNDS, COSMETIC AND DERMATOLOGICAL COMPOSITIONS CONTAINING SAME AND THEIR APPLICATIONS IN PARTICULAR FOR THE TREATMENT OF ALOPECIA
BE1003002A6 (en) Formulation to be applied for the treatment of baldness and methods makinguse thereof
US6465514B1 (en) Methods and compositions for the promotion of hair growth
EP0319028B1 (en) 1,8-hydroxy and/or acyloxy anthracene or anthrone and pyrimidine derivatives to induce and stimulate the hair growth and to reduce hair loss
CA2448829C (en) Preparation for the removal of abnormal keratinous material
IL141515A (en) Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
US5643942A (en) Methods, composition and solutions for treating alopecia
BE1003001A6 (en) Formulation to be applied for the treatment of baldness and methods makinguse thereof
EP0243248A1 (en) Compositions for the treatment of baldness and alopecia
CA1341265C (en) Combination based on pyrimidine derivatives and calcium antagonists to induce and stimulate hair growth and reduce hair loss
US6066676A (en) Pharmaceutical composition and methods for using it
JP5059408B2 (en) Nail preparation
KR101307304B1 (en) Composition for treating hair or scalp to prevent hair loss and promote growing hair
CA1297411C (en) Alkylene diamino quinazoline derivatives based composition for activing and stimulating hair growth and reducing hair loss
BE1001044A5 (en) Composition for induction and stimulate hair growth and reduce their fall based on derivatives pyrimidine.
CN113056269A (en) Use of plasminogen activator inhibitor 1(PAI-1) inhibitors
FR2689008A1 (en) Compsns. for preventing hair loss and promoting regrowth - contain vasodilator e.g. minoxidil, keratolytic agent, and coal tar
JPH11302133A (en) Cosmetic for scalp and hair
KR100476069B1 (en) A composition for trichogenousness or preventing the depilation containing 1,2-dithiolthione derivative

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: COPPE JAN

Effective date: 19910331